Thrombin is a serine protease that plays a pivotal role in thrombosis
and hemostasis, and is a major target for anticoagulation and cardiova
scular disease therapy. Using a novel in vitro selection/amplification
technique, we have identified a new class of thrombin inhibitors base
d on single-stranded DNA (ssDNA) oligodeoxyribonucleotides (oligos). T
hese thrombin inhibitors are the first example of the use of this tech
nique to obtain ssDNA oligos that bind a target protein that does not
interact physiologically with nucleic acid. Here, we review how iterat
ive selection and amplification were used to identifiy short ssDNA seq
uences that bind and inhibit thrombin (Beck et al., Nature 355 (1992)
564-566), and the tertiary structure of one aptamer sequence (Wang et
al., Biochemistry 32 (1993) 1899-1904). Results from in vitro and in v
ivo studies are also summarized (Griffin et al., Blood 81 (1993) 3271-
3276). The discovery of a new class of thrombin inhibitors using this
technology demonstrates the power of this new approach for rapid drug
discovery and development.